Genesis Drug Discovery & Development (GD3) has expanded its drug development services through the acquisition of a majority interest in NexusPharma. The acquisition creates a fully-integrated portfolio of services for GD3 by integrating NexusPharma’s collection of patient-derived xenograft (PDX) models, with GD3’s existing platforms which include syngeneic/cell line derived xenograft models, radiotherapy, flow cytometry, and in-vivo imaging modalities.    With direct access to ...